MaxCyte, Inc. (MXCT)
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
$1.59-8.09%
Close 2026-10-30 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
Research Workspace
Put MXCT beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care Equipment: fringe margins under pressure (4q confirmed)
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Address Nasdaq minimum bid price rule: Direct metric needs a verified mapping.
View ThesisRevenue is contracting — down about 13% over the past year.
View GrowthMiddle-of-the-pack management execution.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is volatile — it swings about 2% on a typical day and fell roughly 62% in its worst 12-month stretch.
View RiskMaxCyte’s case rests on meeting its raised 2026 revenue guidance, though the recorded Q2 revenue trend declined. Q2 FY2026 revenue fell 15% year over year; EPS beat estimates by 33.3%. MXCT trades at 6× sales versus 2.9× for peers, above its 4.1× historical multiple. The price reflects less growth than our forecast. A 38% modeled next-quarter miss probability threatens that growth case. The 6× multiple must be earned against the peer gap. The primary pillar is under pressure because Nasdaq minimum-bid mapping remains unverified. Peer multiples imply a price about 16% below where it trades; the thesis is on watch. This read is provisional.
Trailing returns as of 2026-10-30. MXCT is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 6 analysts currently covering MXCT (as of Oct 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare MXCT with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| MXCT Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 2 valuation methods, at three horizons. As of 2026-10-30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Equipment — fair value, gap to price, and forward P/E.
Compare the value case
Put MXCT next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Achieve 2026 revenue guidance of $30-32 million
Increased revenue guidance supports growth objectives.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Below average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Advances: Achieve 2026 revenue guidance of $30-32 million
Earnings call confirms revenue guidance and strategic direction.
Advances: Advance SPL portfolio clinical programs and partnerships
Strategic pivot supports advancement of clinical programs.
Advances: Achieve 2026 revenue guidance of $30-32 million
Transcript details support revenue outlook.
Advances: Achieve 2026 revenue guidance of $30-32 million
Reiterates revenue outlook, bolstered by partnership.
Threatens: Achieve 2026 revenue guidance of $30-32 million
Revenue forecast exceeded but shares fell, indicating concerns.
